KEVIN F MCLAUGHLIN
CIK 1214938 · SVP, CFO and Treasurer · last filed 2026-05-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$880.3K
Companies
5
Total Filings
90
Lifetime Open-Market Net
-$30.51M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IVVD | Director | 50,000 | $0.54 | $27.2K | $125.0K | 4 | 2026-05-21 |
| VCEL | Director | 18,300 | $46.62 | $853.1K | -$2.37M | 21 | 2026-05-15 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 0 | $4.91 | $0 | $0 | 3 | 2023-09-25 |
| ACCELERON PHARMA INC (XLRN) Delisted | SVP, CFO and Treasurer | 0 | $178.75 | $0 | -$28.26M | 53 | 2021-11-22 |
| PRCS | President and CEO | 0 | $27.85 | $0 | $0 | 1 | 2007-02-08 |
Recent Filings · Page 7 of 9
90 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-07-06 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −10,000 | -$796.1K | EDGAR |
| 2016-05-25 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | −25,000 | -$858.6K | EDGAR |
| 2016-05-06 | VCEL | Grant (A) | — | $0 | EDGAR |
| 2016-03-07 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +5,100 | $0 | EDGAR |
| 2015-12-23 | ACCELERON PHARMA INC (XLRN) Delisted | Exer (M) | +7,500 | $29.1K | EDGAR |
| 2015-10-09 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$143.5K | EDGAR |
| 2015-09-11 | ACCELERON PHARMA INC (XLRN) Delisted | Grant (A) | +40,000 | $0 | EDGAR |
| 2015-09-10 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$170.8K | EDGAR |
| 2015-08-12 | ACCELERON PHARMA INC (XLRN) Delisted | Mixed | — | -$160.2K | EDGAR |
| 2015-07-30 | ACCELERON PHARMA INC (XLRN) Delisted | Exer (M) | +5,000 | $19.4K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.